Neupath Health appoints Lemieux as CEO

Executive Summary

• Neupath Health Inc. announced a planned executive leadership transition effective April 1, 2026, where President Stephen Lemieux will succeed Joseph Walewicz as CEO.
• The company pre-announced strong preliminary financial results for fiscal 2025, projecting total revenue between $86 million and $88 million and adjusted EBITDA between $5.6 million and $6.0 million.
• Sandee Dela Cruz was promoted to Chief Information Officer effective January 1, 2026, while outgoing CEO Joseph Walewicz will remain on the board of directors and in a consulting capacity.

Key Details

• CEO Transition: Stephen Lemieux becomes CEO on April 1, 2026, succeeding Joseph Walewicz.
• CIO Promotion: Sandee Dela Cruz promoted to Chief Information Officer effective January 1, 2026.
• Outgoing CEO Role: Joseph Walewicz remains on the board of directors and will provide strategic guidance in a consulting capacity.
• 2025 Revenue Guidance: Preliminary total revenue expected to be in the range of $86 million to $88 million (compared to $72.8 million in 2024).
• 2025 EBITDA Guidance: Preliminary adjusted EBITDA expected to be between $5.6 million and $6.0 million (compared to $3.8 million in 2024).
• Audit Date: Audited 2025 results are expected to be reported on March 26, 2026.
• CEO Background: Stephen Lemieux has over 20 years of experience in finance and operations, including multiple CFO roles and an interim CEO role in public healthcare companies; he previously led the acquisition of HealthPointe in 2021.
• CIO Background: Sandee Dela Cruz has over 20 years of experience in technology innovation and business transformation, recognized as a Top 10 Mid-Market CIO by Info-Tech in 2015, 2020, and 2023.

Notable Quotes

• "I am honoured to become Neupath's next CEO. I am familiar with our team, the complexity of our business and the opportunities to continue growing Neupath, which will enable a smooth transition of responsibilities from Joe. I look forward to working with our talented and passionate team, as we continue to grow our business," said Mr. Lemieux.
• "The board and I would like to thank Joe for his leadership over the past three and a half years and for leading an extensive program of corporate and operational improvements... With Stephen as CEO, Jeff Zygouras as CFO and Sandee as CIO, we are confident in the continued success and execution of Neupath's significant growth strategy," said Jolyon Burton, director and key shareholder.